Maravai LifeSciences Holdings, Inc.
In the published model solve dated 2026-Q2, anchored at $6.40, Maravai LifeSciences Holdings, Inc. (MRVI) is priced for today's economics sustained for ~9.4 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
The single decisive number is the EBITDA swing. Q1 2026 adjusted EBITDA turned positive at $20.3 million from a $10.5 million loss a year earlier, and free cash flow went positive, the clearest sign Maravai's downcycle has bottomed. The revenue inflection is real but mixed. Q1 revenue rose 40.5% to $65.8 million, led by TriLink, though a large chunk came from volatile high-volume CleanCap orders for commercial COVID vaccines rather than the steadier base business. The valuation already prices
Is MRVI overvalued? See what's priced in →
153 institutional managers reported holding MRVI in 13F filings for the quarter ended 2026-03-31. Together they hold about 83% of the company; the top 10 hold 51%. 22 opened new positions that quarter. Held by BlackRock, Vanguard Group, Renaissance Technologies, among others. On the short side, 8.7M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
MRVI's share count grew 30.5% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at MRVI over the trailing three years: 2024: 2 buys totaling $1.09M; 2025: 5 buys totaling $1.88M. 20 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
MRVI's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | -3.5% | -21.4% |
| 2023-11-09 | -31.3% | +39.8% |
| 2024-03-01 | +58.9% | +18.2% |
| 2024-05-10 | +10.0% | -14.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
MRVI's latest 8-K filings: 2026-08-06 (items 2.02, 9.01); 2026-06-03 (items 1.01, 1.02, 2.03, 7.01, 9.01); 2026-05-29 (items 5.07); 2026-05-07 (items 2.02, 9.01); 2026-02-25 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.